A Pilot Study to Evaluate The Efficacy of Adapalene 0.3% for Use in the Prevention and Treatment of Senile Purpura

This is a new potential use for the product Adapalene 0.3%, which is currently an FDA
approved topical treatment used for the treatment of acne.

Senile purpura is a common sign of aging that appears in the form of dark blotches on the
skin and is caused by bruising.

Older adults tend to be more prone to bruising, since as people age, their skin becomes
thinner and more fragile.

Inclusion Criteria:

- Male or female over 52 years of age with signs of senile purpura on either the right
or left (or both) dorsal hand & extensor forearm and desire treatment for this
condition that is associated with aging.

- Women who have had hysterectomies, tubal ligations or who are post-menopausal for at
least one year prior to the study may be enrolled. Women of childbearing potential
who are not pregnant, not planning to become pregnant during the study period, and
not lactating may be enrolled if they are using a medically accepted contraceptive
program initiated at least one month prior to study entry and continued during the
study.

- Subject is willing to comply with study instructions and return to the clinic for
required visits.

- Subject is able to understand and has signed an IRB approved informed consent form
including consent for photography.

Exclusion Criteria:

- All subjects on coumadin, heparin, plavix, supplemental herbs, vitamin E, empirin,
fiorinal, norgesic, forte, percodan, robaxin, nuprin, ansaid, anaprox, clinoril,
dolobid, feldene, naprosyn, voltaren, fish oil, oral steroids, or daily use of
aspirin, Motrin, or Advil. (PRN usage not excluded)

- Prior treatment with any systemic immunosuppressive therapy including but not limited
to chemotherapy agents or corticosteroids within 3 months of study enrollment is
prohibited.

- Clotting abnormalities as determined by screening labs

- Any history of a stroke or unstable heart disease

- Participation in another clinical trial with exposure to any investigational agent
within 30 days prior to Screening Visit.

- Any condition the Investigator believes would interfere with subject's ability to
provide informed consent, comply with study instruction, or which might confound the
interpretation of the study results or put the subject at undue risk.

- Subject is pregnant, breastfeeding or planning a pregnancy during the study.

- Subject is unable to communicate or cooperate with the Investigator due to a language
barrier (non-English speaking).

- Subjects who are allergic to adapalene or the ingredients in the gel.